Invo BioScience Retained Earnings (Accumulated Deficit) 2010-2024 | NAYA
Invo BioScience retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Invo BioScience Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-58 |
| 2022 |
$-50 |
| 2021 |
$-39 |
| 2020 |
$-32 |
| 2019 |
$-24 |
| 2018 |
$-22 |
| 2017 |
$-19 |
| 2016 |
$-18 |
| 2015 |
$-16 |
| 2014 |
$-11 |
| 2013 |
$-9 |
| 2012 |
$-8 |
| 2011 |
$-8 |
| 2010 |
$-7 |
| 2009 |
$-7 |
Invo BioScience Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-62 |
| 2024-03-31 |
$-59 |
| 2023-12-31 |
$-58 |
| 2023-09-30 |
$-56 |
| 2023-06-30 |
$-55 |
| 2023-03-31 |
$-52 |
| 2022-12-31 |
$-50 |
| 2022-09-30 |
$-47 |
| 2022-06-30 |
$-44 |
| 2022-03-31 |
$-42 |
| 2021-12-31 |
$-39 |
| 2021-09-30 |
$-39 |
| 2021-06-30 |
$-37 |
| 2021-03-31 |
$-35 |
| 2020-12-31 |
$-32 |
| 2020-09-30 |
$-28 |
| 2020-06-30 |
$-27 |
| 2020-03-31 |
$-25 |
| 2019-12-31 |
$-24 |
| 2019-09-30 |
$-23 |
| 2019-06-30 |
$-22 |
| 2019-03-31 |
$-22 |
| 2018-12-31 |
$-22 |
| 2018-09-30 |
$-21 |
| 2018-06-30 |
$-21 |
| 2018-03-31 |
$-19 |
| 2017-12-31 |
$-19 |
| 2017-09-30 |
$-18 |
| 2017-06-30 |
$-18 |
| 2017-03-31 |
$-18 |
| 2016-12-31 |
$-18 |
| 2016-09-30 |
$-18 |
| 2016-06-30 |
$-17 |
| 2016-03-31 |
$-16 |
| 2015-12-31 |
$-16 |
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2011-12-31 |
$-8 |
| 2011-09-30 |
$-8 |
| 2011-06-30 |
$-7 |
| 2011-03-31 |
$-7 |
| 2010-12-31 |
$-7 |
| 2010-09-30 |
$-7 |
| 2010-06-30 |
$-6 |
| 2010-03-31 |
$-6 |
| 2009-12-31 |
$-7 |
| 2009-09-30 |
$-7 |
| 2009-06-30 |
$-3 |
| 2009-03-31 |
$-3 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.004B |
$0.003B |
|
INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. It engages in the development and manufacture of its lead product, INVOcell, a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience focuses on selling its product to IVF centers and physicians through distributors, as well as directly to physicians in Europe, Canada, Latin America, and the Middle East.
|
